Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients.
about
Hyperphosphatemia Management in Patients with Chronic Kidney DiseasePlasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a Cross-Sectional Observational StudySevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics.Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers.Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part DHypertension and hyperparathyroidism are associated with left ventricular hypertrophy in patients on hemodialysisCompounds in development to combat hyperphosphataemia.The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure.Management of secondary hyperparathyroidism of dialysis patients.Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value.Medical and surgical treatment for secondary and tertiary hyperparathyroidism.Cinacalcet HCl: a novel therapeutic for hyperparathyroidism.Calcium loading, calcium accumulation, and associated cardiovascular risks in dialysis patients.Current treatment options in secondary renal hyperparathyroidism.Sevelamer carbonate experience in Indian end stage renal disease patients.Phosphate binders: new products and challenges.Management of hyperphosphatemia.Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patientsEfficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysisThe Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.Emerging drugs for hyperphosphatemia.Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis.Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients.Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V).Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.Update and critical appraisal of sevelamer in the management of chronic renal failure.Optimal use of phosphate binders in chronic kidney disease.Phosphate overload accelerates vascular aging in uremic patients.Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies.Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremiaProspective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.Reconsidering the importance of long-term low-level aluminum exposure in renal failure patients.Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethics.Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis.Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia.Switching from calcium carbonate to sevelamer hydrochloride has suppressive effects on the progression of aortic calcification in hemodialysis patients: assessment using plain chest X-ray films.Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride.
P2860
Q26743842-C5CB47EF-1DDB-4B93-B5AA-B08D7A06AE5CQ28535870-533F633C-F40E-4F40-993E-30C15CF19E0BQ32039075-03C62CD0-F1FF-4E69-B9EA-C8200A7F3E85Q32039092-6ED0C65B-4CF2-4CBB-8781-CF70889FEE46Q33432770-1D05D44C-3BAC-4984-B683-9526B75636F5Q33801022-3664E2F3-1923-4CC1-B718-935B2054E304Q33873935-676685FE-7FC5-4E1E-83AA-D9ED5E896F1BQ34481935-63E2BDB9-F44E-46E6-BCAC-C9A9D9922475Q34506934-4572143B-A8C8-4F0D-BE6D-FF7F373CEBDBQ35687612-96E767EF-64DE-4428-8A81-FAA2AAD35369Q35876363-FC447CF1-FD0C-4BFB-9CDA-B06BCE7D83E7Q36013623-0BC741C2-C94D-4A97-B85F-CAD0D9F7DA7DQ36082068-3E6C8494-C57A-43CA-AAC8-02C0C7195B7AQ36098776-BFDEAF75-13C0-4125-AB33-C53AD3EDE168Q36250191-822A237D-096B-4167-8C2B-41790C7B4B36Q36283544-F6D2C12A-499A-4CAA-9C07-96E300092727Q36522027-BA93E8C1-DEF4-47D7-99E8-63CCB99E6615Q36609857-567C0523-5B59-4A14-8AEA-41B4265535C8Q36666977-232DCB27-62D0-4294-BD16-191F81BCE6CDQ36736647-6C58E7C5-98A0-489A-AA69-6F777F0F53E4Q36904701-1BC9F4D1-DA18-4059-95CE-5C5B3886DB39Q36944004-3186281E-158F-4A76-8B10-3909B6B98C7CQ37099010-ECD951F5-107C-4A32-8D96-DB47EA13384CQ37430181-E03173BE-9A7E-4340-94B7-D8B897D69B0CQ37449096-16D43F9A-4C94-4EF8-8BD5-3F044501FBFFQ37803240-9B8D616A-24AD-4682-ABD2-C45DBBBA28C1Q38079128-0F8BAE47-30E8-46CD-85A6-46049916706BQ38160473-C2290FC8-0EF0-41A6-AEBA-D90603887C80Q38161580-0C8B369D-CE25-4E47-A1B7-177A71BF2002Q38605311-72A7EC44-097D-4D0F-A5B2-ACEE968D315EQ39220825-BAA4D026-5530-4E2F-A06C-3C7B7972DC18Q40106776-B7A78E5A-7C66-488F-8E9B-EDD52D9AAC48Q42142326-34DEC4DF-974E-4A5E-990F-FFD360B3C381Q42664078-27696904-F8A2-439E-B951-4AC144DE94D8Q43530564-76152C84-786A-4515-8607-07AABBCB10DAQ43843591-9846D6BA-5475-4C99-8A30-C498DD5BA29CQ44853372-9C205C08-21FC-4941-B831-580E94864967Q44874910-65A26F53-EDCB-4CA2-A9D4-A86747947CC1Q46240729-B77CB438-DEA1-44E3-83DF-FB2BAACA13F2Q46418929-280E37F8-7FBF-4C9B-81A2-9E64E9ECAAFC
P2860
Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Long-term effects of sevelamer ...... ile of haemodialysis patients.
@en
type
label
Long-term effects of sevelamer ...... ile of haemodialysis patients.
@en
prefLabel
Long-term effects of sevelamer ...... ile of haemodialysis patients.
@en
P2093
P356
P1476
Long-term effects of sevelamer ...... ile of haemodialysis patients.
@en
P2093
Chertow GM
Slatopolsky E
P304
P356
10.1093/NDT/14.12.2907
P407
P577
1999-12-01T00:00:00Z